ライフサイエンスコーパス: viral hemagglutinin

1 nd neutralizing humoral immunity against the viral hemagglutinin.

2 nd neutralizing humoral immunity against the viral hemagglutinin.

3 rrent vaccine containing 2009 (Cal0709) H1N1 viral hemagglutinin.

4 dulate the dissociation of nectin-4 from the viral hemagglutinin.

5 ry capacity to escape immunity targeting the viral hemagglutinin.

6 ies that react with the globular head of the viral hemagglutinin.

7 pitopes, the antibody-binding domains of the viral hemagglutinin.

8 with specificity to the stalk domain of the viral hemagglutinin.

9 s via binding of cell-surface glycans by the viral hemagglutinin.

10 by blocking membrane fusion mediated by the viral hemagglutinin.

11 ctions, each composed of a dimer of VP4, the viral hemagglutinin.

12 tal globular head domain of their respective viral hemagglutinins.

13 adaptive mutations occurred in the gene for viral hemagglutinin, a gene that frequently acquires cha

14 the N-terminal fragment, VP8*, which is the viral hemagglutinin and an important target of neutraliz

15 s of adaptive evolution, most notably in the viral hemagglutinin and compatible with the action of an

16 duced nonsynonymous genetic diversity in the viral hemagglutinin and nucleoprotein, and (iii) intraho

17 ne renal cell carcinoma expressing influenza viral hemagglutinin as a defined surrogate antigen (Renc

18 y selectively blocking the maturation of the viral hemagglutinin at a stage preceding resistance to e

19 argeted cell population, we displayed on the viral hemagglutinin (H) a single-chain antibody (scAb) s

20 he method, the optimization was done using a viral hemagglutinin (HA) as a model protein and then app

21 potential of highly conserved regions of the viral hemagglutinin (HA) as targets for broadly neutrali

22 the sialic acid (SA) receptors to which the viral hemagglutinin (HA) binds.

23 antibodies against conserved epitopes on the viral hemagglutinin (HA) could confer immunity to the di

24 demic influenza vaccine that deliver various viral hemagglutinin (HA) doses with or without AS03 (a t

25 While the importance of antibody to viral hemagglutinin (HA) has long been recognized, the l

26 d in this study a novel DNA vaccine in which viral hemagglutinin (HA) is bivalently targeted to MHC c

27 Here, we uncovered that influenza viral hemagglutinin (HA) protein causes the degradation

28 eceptors, NKp44 and NKp46, interact with the viral hemagglutinin (HA) protein expressed on the cell s

29 ecific for the immunodominant epitope of the viral hemagglutinin (HA) protein.

30 TCR transgenic mice (TS1) specific for viral hemagglutinin (HA) provided antigen-specific T cel

31 o experimentally introduced mutations in the viral hemagglutinin (HA) receptor-binding domain conferr

32 lied the above approach to analyze influenza viral hemagglutinin (HA) sequences.

33 ty directed against the stalk domains of the viral hemagglutinin (HA) show promise for protecting aga

34 es in the receptor binding site (RBS) of the viral hemagglutinin (HA) that alter receptor preference

35 s irreversible conformational changes of the viral hemagglutinin (HA) that drive the membrane fusion

36 tical is the acquisition of mutations on the viral hemagglutinin (HA) to "quantitatively switch" its

37 -specific mAbs target the head domain of the viral hemagglutinin (HA), whereas broadly reactive mAbs

38 ions in the proteolytic cleavage site of the viral hemagglutinin (HA), which activates HA and exposes

39 bodies recognizing conserved surfaces on the viral hemagglutinin (HA).

40 ntibodies targeting the globular head of the viral hemagglutinin (HA).

41 ucture, including addition of glycans to the viral hemagglutinin (HA).

42 ral and endosomal membranes catalyzed by the viral hemagglutinin (HA).

43 ed against the conserved stalk domain of the viral hemagglutinin have attracted increasing attention

44 Viral hemagglutinin is a homotrimeric receptor, and thus

45 induce IgE class switching, suggesting that viral hemagglutinin is involved in this synergistic effe

46 us (NDV) requires an interaction between the viral hemagglutinin-neuraminidase (HN) and fusion (F) pr

47 type 3 (HPF3) require the interaction of the viral hemagglutinin-neuraminidase (HN) glycoprotein with

48 us type 3 (HPF3) requires interaction of the viral hemagglutinin-neuraminidase (HN) glycoprotein with

49 Coexpression of M protein with the viral hemagglutinin-neuraminidase (HN) or fusion (F) gly

50 ote fusion of Cos-7 cells independent of the viral hemagglutinin-neuraminidase (HN) protein and exhib

51 , initiates infection with attachment of the viral hemagglutinin-neuraminidase (HN) protein to sialic

52 that bind the conserved stalk domain of the viral hemagglutinin of H1 and H5 subtypes and protect mi

53 tion and performed similarly for recombinant viral hemagglutinin protein detection.

54 eptide (IFP) is the N-terminal domain of the viral hemagglutinin protein, binds to the endosomal memb

55 a process of membrane fusion mediated by the viral hemagglutinin protein.

56 hat the EB peptide specifically binds to the viral hemagglutinin protein.

57 acid mutations at key antigenic sites of the viral hemagglutinin protein.

58 Sequence analysis of the viral hemagglutinin receptor-binding domain performed on

59 d with virion aggregation and coating of the viral hemagglutinin receptor; however, viral lysis did n

60 have been reported to bind the stalk of the viral hemagglutinin, suggesting that a vaccine based on

61 haracterizing the binding specificity of the viral hemagglutinin to the sialylated glycan receptors (

62 Among those, a mutation in the viral hemagglutinin was identified that increases 2009 p

63 e any clustering or spatial rearrangement of viral hemagglutinin, which affects the rate-limiting ste

64 protein, and no changes were observed in the viral hemagglutinin, which is the receptor attachment pr